Havens Advisors LLC Acquires Shares of 165,000 Ignyta Inc (RXDX)

Havens Advisors LLC acquired a new stake in Ignyta Inc (NASDAQ:RXDX) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 165,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,406,000. Ignyta comprises approximately 3.3% of Havens Advisors LLC’s investment portfolio, making the stock its 11th biggest holding. Havens Advisors LLC owned approximately 0.24% of Ignyta as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of RXDX. Schwab Charles Investment Management Inc. raised its position in Ignyta by 28.5% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 117,745 shares of the biopharmaceutical company’s stock valued at $1,219,000 after purchasing an additional 26,100 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Ignyta by 65.1% in the 2nd quarter. Rhumbline Advisers now owns 53,189 shares of the biopharmaceutical company’s stock valued at $551,000 after buying an additional 20,968 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Ignyta by 50.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 165,981 shares of the biopharmaceutical company’s stock valued at $1,718,000 after buying an additional 55,388 shares during the period. Legal & General Group Plc increased its stake in shares of Ignyta by 71.9% in the 2nd quarter. Legal & General Group Plc now owns 12,681 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 5,306 shares during the period. Finally, Wells Fargo & Company MN increased its stake in shares of Ignyta by 2.3% in the 2nd quarter. Wells Fargo & Company MN now owns 22,385 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 500 shares during the period. Hedge funds and other institutional investors own 71.51% of the company’s stock.

Shares of Ignyta Inc (NASDAQ:RXDX) traded down $0.15 during trading on Wednesday, hitting $26.80. The company had a trading volume of 3,194,300 shares, compared to its average volume of 3,995,820. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.34. Ignyta Inc has a twelve month low of $4.60 and a twelve month high of $27.10. The firm has a market capitalization of $1,821.52, a PE ratio of -9.93 and a beta of 2.11.

Ignyta (NASDAQ:RXDX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.03. research analysts predict that Ignyta Inc will post -2.27 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on the company. Zacks Investment Research cut Ignyta from a “buy” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald set a $23.00 target price on Ignyta and gave the company a “buy” rating in a research note on Thursday, December 28th. Jefferies Group cut Ignyta from a “buy” rating to a “hold” rating and set a $27.00 target price for the company. in a research note on Thursday, December 28th. SunTrust Banks cut Ignyta from a “buy” rating to a “hold” rating and lifted their target price for the company from $25.00 to $27.00 in a research note on Tuesday, December 26th. Finally, Ladenburg Thalmann Financial Services cut Ignyta from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 26th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $26.33.

TRADEMARK VIOLATION WARNING: “Havens Advisors LLC Acquires Shares of 165,000 Ignyta Inc (RXDX)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://weekherald.com/2018/01/17/havens-advisors-llc-acquires-shares-of-165000-ignyta-inc-rxdx.html.

About Ignyta

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply